Journal
ONCOTARGET
Volume 6, Issue 40, Pages 42923-42937Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.5976
Keywords
cancer stem cell marker; integrin; AMPK; mTOR; OSU-CG5
Categories
Funding
- Ministry of Science and Technology, Taiwan, Republic of China [NSC 97-2320-B-006-003-MY3]
- Innovative and Exploratory Project from National Cheng Kung University [B035]
- National Health Research Institute, Taiwan [NHRI-EX100-9927B1]
- Department of Health, Executive Yuan, Taiwan [DOH101-TD-C-111-003]
Ask authors/readers for more resources
CD90 is used as a marker for cancer stem cell in liver cancer. We aimed to study the mechanism by which CD90 promoted liver cancer progression and identify the new therapeutic targets on CD90 signal pathway. Ectopic expression of CD90 in liver cancer cell lines enhanced anchorage-independent growth and tumor progression. Furthermore, CD90 promoted sphere formation in vitro and upregulated the expression of the cancer stem cell marker CD133. The CD133 expression was higher in CD45-CD90+ cells in liver cancer specimen. The natural carcinogenic molecules TGF-beta-1, HGF, and hepatitis B surface antigen increased the expression of CD90 and CD133. Inhibition of CD90 by either shRNA or antibody attenuated the induction of CD133 and anchorage-independent growth. Lentiviral delivery of CD133 shRNA abolished the tumorigenicity induced by CD90. Ectopic expression of CD90 induced mTOR phosphorylation and AMPK dephosphorylation. Mutation of integrin binding-RLD domain in CD90 attenuated the induction of CD133 and anchorage-independent growth. Similar results were observed after silencing beta 3 integrin. Signaling analyses revealed that AMPK/mTOR and beta 3 integrin were required for the induction of CD133 and tumor formation by CD90. Importantly, the energy restriction mimetic agent OSU-CG5 reduced the CD90 population in fresh liver tumor sample and repressed the tumor growth. In contrast, sorafenib did not decrease the CD90+ population. In conclusion, the signal axis of CD90-integrin-mTOR/AMPK-CD133 is critical for promoting liver carcinogenesis. Molecules inhibiting the signal axis, including OSU-CG5 and other inhibitors, may serve as potential novel cancer therapeutic targets in liver cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available